The Effectiveness of Phytotherapy in SARS-COV2(COVID-19) (Quercetix)

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination. Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America. At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies. History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

a Randomized Double-blind Study, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), PHYTOTHERAPIE

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.

Inclusion Criteria: all patients attending the emergency department for influenza-like illness. Being over 18 years old Exclusion Criteria: Any patient requiring admission Non-consenting patients